American Century Companies
HOWL icon

American Century Companies’s Werewolf Therapeutics HOWL Stock Holding History

American Century Companies’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,511
Closed -$62.9K – 2912
2024
Q4 		$62.9K Buy
42,511
+1,098
+3% +$2.24K ﹤0.01% 2863
2024
Q3 		$87.8K Buy
41,413
+3,779
+10% +$8.6K ﹤0.01% 2844
2024
Q2 		$91.8K Buy
37,634
+12,656
+51% +$60.8K ﹤0.01% 2830
2024
Q1 		$162K Buy
+24,978
New +$146K ﹤0.01% 2796

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies's HOWL Position: Q1 2025 in Review

American Century Companies sold out of Werewolf Therapeutics (HOWL) in Q1 2025, closing a stake of 42,511 shares — an estimated $62.9K sold.

American Century Companies first reported a position in HOWL in Q1 2024 and held it in 4 quarters. The position peaked at $162K in Q1 2024. 70 funds tracked by Wall St. Rank hold HOWL as of Q1 2025.

  • American Century Companies reported no remaining Werewolf Therapeutics position as of Q1 2025 after selling out during the quarter.
  • American Century Companies sold 42,511 Werewolf Therapeutics shares in Q1 2025, an estimated $62.9K.
  • American Century Companies first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 4 quarters.
  • American Century Companies's Werewolf Therapeutics position peaked at $162K in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2025.

Based on American Century Companies's 13F filing for Q1 2025, filed 13 May 2025.